Antiemetics: an update and the MASCC guidelines applied in clinical practice

J. Herrstedt

Antiemetics: an update and the MASCC guidelines applied in clinical practice

83 Citations (Scopus)

Abstract

Nausea and vomiting are two of the most severe problems for patients treated with chemotherapy. Until the late 1970s, nausea and vomiting induced by chemotherapy was an almost neglected research area. With the introduction of cisplatin, the cytotoxin with the highest emetic potential, research was stimulated and has now resulted in the development of two new classes of antiemetics, the serotonin and neurokinin antagonists. A large number of trials have fine-tuned antiemetic therapy and made evidence-based recommendations possible for the majority of patients receiving chemotherapy. This Review discusses the pathophysiology of nausea and vomiting, the development of antiemetics, highlights some of the newest antiemetics, and finally summarizes recommendations from the evidence-based guidelines developed by the Multinational Association of Supportive Care in Cancer
Udgivelsesdato: 2008/1

Original language	English
Journal	Nature Clinical Practice Oncology
Volume	5
Issue number	1
Pages (from-to)	32-43
Number of pages	11
ISSN	1743-4254
Publication status	Published - 2008

Cite this

@article{a5c8f490059511deb05e000ea68e967b,

title = "Antiemetics: an update and the MASCC guidelines applied in clinical practice",

abstract = "Nausea and vomiting are two of the most severe problems for patients treated with chemotherapy. Until the late 1970s, nausea and vomiting induced by chemotherapy was an almost neglected research area. With the introduction of cisplatin, the cytotoxin with the highest emetic potential, research was stimulated and has now resulted in the development of two new classes of antiemetics, the serotonin and neurokinin antagonists. A large number of trials have fine-tuned antiemetic therapy and made evidence-based recommendations possible for the majority of patients receiving chemotherapy. This Review discusses the pathophysiology of nausea and vomiting, the development of antiemetics, highlights some of the newest antiemetics, and finally summarizes recommendations from the evidence-based guidelines developed by the Multinational Association of Supportive Care in Cancer Udgivelsesdato: 2008/1",

author = "J. Herrstedt",

year = "2008",

language = "English",

volume = "5",

pages = "32--43",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "nature publishing group",

number = "1",

}

TY - JOUR

T1 - Antiemetics: an update and the MASCC guidelines applied in clinical practice

AU - Herrstedt, J.

PY - 2008

Y1 - 2008

N2 - Nausea and vomiting are two of the most severe problems for patients treated with chemotherapy. Until the late 1970s, nausea and vomiting induced by chemotherapy was an almost neglected research area. With the introduction of cisplatin, the cytotoxin with the highest emetic potential, research was stimulated and has now resulted in the development of two new classes of antiemetics, the serotonin and neurokinin antagonists. A large number of trials have fine-tuned antiemetic therapy and made evidence-based recommendations possible for the majority of patients receiving chemotherapy. This Review discusses the pathophysiology of nausea and vomiting, the development of antiemetics, highlights some of the newest antiemetics, and finally summarizes recommendations from the evidence-based guidelines developed by the Multinational Association of Supportive Care in Cancer Udgivelsesdato: 2008/1

AB - Nausea and vomiting are two of the most severe problems for patients treated with chemotherapy. Until the late 1970s, nausea and vomiting induced by chemotherapy was an almost neglected research area. With the introduction of cisplatin, the cytotoxin with the highest emetic potential, research was stimulated and has now resulted in the development of two new classes of antiemetics, the serotonin and neurokinin antagonists. A large number of trials have fine-tuned antiemetic therapy and made evidence-based recommendations possible for the majority of patients receiving chemotherapy. This Review discusses the pathophysiology of nausea and vomiting, the development of antiemetics, highlights some of the newest antiemetics, and finally summarizes recommendations from the evidence-based guidelines developed by the Multinational Association of Supportive Care in Cancer Udgivelsesdato: 2008/1

M3 - Journal article

SN - 1759-4774

VL - 5

SP - 32

EP - 43

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 1

ER -